ArticleESMO open2026
A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer associates with a sustained risk of relapse over time. Current multigene assays offer limited validity to identify clinically low-risk tumors at high risk of recurrence, which is particularly relevant in the context of novel adjuvant therapies. In this study, we developed and validated ER-Predict, a machine learning assay leveraging a 14-gene expression signature to classify early stage HR-positive/HER2-negative breast cancer according to the risk of relapse. MATERIALS AND
methodsER-Predict was developed on a cohort of 1413 HR-positive/HER2-negative early breast cancer cases. External validation was carried out across eight publicly available cohorts (n = 1118). Comparative benchmarking was conducted against reproduced prognostic signatures, and particularly, EndoPredict and Oncotype DX. Functional annotation and drug response analysis were carried out using gene expression and pharmacogenomic data from publicly available breast cancer cell lines.
resultsER-Predict identified high-risk patients with significantly reduced distant metastasis-free survival in the external validation cohort (hazard ratio 2.03, 95% confidence interval 1.57-2.63, P < 0.0001). The assay demonstrated independent prognostic value beyond traditional clinicopathological factors, including tumor grade, tumor size, and nodal status, and consistently outperformed recomputed multigene panels. ER-Predict showed specificity toward luminal-like transcriptomic programs, revealing activation of key cell-cycle regulators governing endocrine resistance among high-risk tumors that had retained expression of retinoblastoma-1, suggesting potential actionability by means of cell-cycle inhibitors.
conclusionsER-Predict represents a robust assay with potential utility in early stage HR-positive/HER2-negative breast cancer. Its consistent ability to identify high-risk patients supports further investigation as a decision-support tool to guide treatment intensification in clinically low-risk HR-positive/HER2-negative disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.